Compare Neurocrine Biosciences Inc (NBIX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vital Farms Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Vital Farms Inc trades at $9.37 (market cap $405.27M). The key difference: Neurocrine Biosciences Inc is far larger — about 35.4× Vital Farms Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Vital Farms Inc for 14 Days on average.
| NBIX | VITL | |
|---|---|---|
Market Cap | $14.36B | $405.27M |
Volume | 1,237,180 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $43.68 |
52-Week Low | $123.10 | $8.28 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $14.37B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Vital Farms (VITL) trades at $9.36, up 1.3% on the day, amid a challenging period marked by recent earnings misses and a bearish technical signal. The stock shows weak profitability with a net margin of 0.02% in 2026, though valuation ratios like P/E of 11.77 and P/S of 0.55 appear modest. Recent news highlights strategic review speculation and institutional buying interest, providing some positive sentiment against operational headwinds.
The outlook remains cautious due to earnings volatility and cash flow concerns, but analyst consensus is bullish with a $13.11 price target. Key risks include egg pricing pressure and execution challenges, while potential upside hinges on strategic moves and demand recovery for pasture-raised eggs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
